The Hypertension Optimal Treatment (HOT ) Study appropriate therapeutic regime it is perfectly possible was initiated in 1992 and tries to address two major to lower blood pressure in the great majority of the issues in essential hypertension. The first is to establish hypertensive population. However, in order to obtain the optimal therapeutic goal in the treatment of hyper-an adequate control of blood pressure, the percentage tension, i.e. whether a diastolic blood pressure of <90, of patients needing the combination of two or more <85 or <80 mmHg is preferable to achieve optimal drugs increases to more than 60% [4] . protection against hypertension-induced morbidity and
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The drop in blood pressure was independent of age, mortality. The second aim is to evaluate the effect of sex, the presence or absence of other associated risk a low dose of acetyl-salicylic acid ( 75 mg daily) com-factors, and of the fact that the patient was or was pared with placebo in the prevention of cardiovascular not receiving previous antihypertensive therapy [4 ] . morbidity and mortality. The rationale and back-Furthermore, the percentage of patients attaining the ground of the HOT Study, as well as the inclusion expected level of control for diastolic blood pressure data of the 19193 patients entering the study have been was significantly higher in elderly (above 65 years of described in detail previously [1, 2] . The Study is con-age) than in younger (ages between 50 and 64) hyperducted in accordance with a PROBE design (prospect-tensives [4] . Another interesting aspect of this study is ive, randomized, open, blinded end-point) evaluation the higher percentage of patients attaining the lowest [3 ] . Every patient has received besides the usual advice level of diastolic blood pressure in United States as on life-style changes 5 mg of felodipine as the starting compared to Europe [7] . This finding indicates that pharmacological therapy, to which in a second step a the attitude of doctors in US is more aggressive than converting enzyme inhibitor or a beta-blocker are in Europe when antihypertensive drugs have to be added if needed; the third step in the pharmacological added to attain the goal of blood pressure control. All approach of the HOT Study contemplates doubling these data allow us to conclude that to lower blood the dose of felodipine to 10 mg/day while maintaining pressure to a given level is possible, although a further the same dose of the second drug. This last is doubled effort will probably be needed to maintain systolic in dose in step four if blood pressure control is not blood pressure in values below 140 mmHg. attained. The fifth and last step contemplates the Many substudies are being conducted simultanadministration of three drugs (felodipine+ACE eously with the main project of the HOT Study. Among inhibitor+beta blocker or the two previously adminis-them are different aspects of renal function. The first tered drugs plus hydrochlorothiazide).
of these aspects investigated has been the influence of The HOT Study is running the third year of follow-renal function level at entry on the attainment of blood up and while the 1100 events needed to address the pressure control in the three different targets of blood two major issues take place some important lessons pressure control. These data have been recently pubhave already been learned from this study. The first lished [8 ] , and interest in them depends on the fact refers to blood pressure control. One-year data for all that the literature indicates that the presence of some patients show that the three targets of diastolic bood degree of renal failure precludes the attainment of an pressure control have been attained in 84, 72, and 57% adequate control of blood pressure in patients with respectively [4 ] . Meanwhile, mean values for systolic essential hypertension [9, 10] . The data obtained in the blood pressure are 144, 142, and 140 mmHg respect-HOT Study show that the presence of an elevated ively [4 ] . These data compare with only 21% of patients serum creatinine does not impede the expected fall in attaining blood pressure levels in the last Joint National blood pressure in order to attain the goal of control. Committee V in US [5] and with similar values of However, they also show that in the presence of an control in Europe [6 ] . This indicates that with an elevated serum creatinine (>1.5 mg/dl, n=468), the number of drugs needed to obtain that control is Optimal use of HLA typing for kidney transplant recipient toward his graft. Similar analysis performed selection is still a matter of discussion. Analysis of in the donor was considered to reflect either a peculiar data gathered by large registries such as the UCLA immunogenicity of the graft or its capacity to generate Tissue Typing Laboratory [1 ] , Eurotransplant [2] , and suppressor mechanisms. As a marker of nonthe Collaborative Transplant Study [3 ] have repeatedly acceptance in the recipient while of good prognosis in confirmed the beneficial effect on graft survival of the donor, the influence of the DR6 antigen, originally matching between donor and recipient. Taking into described by the group of Leiden, became the illustraconsideration antigens belonging to the HLA-A, -B tion of this paradigm [2 ] . In our centre, the beneficial and -DR loci, it is clear that the zero ABDR mismatch influence of the DR5 both in the donor and the ( MM) provides the best survival rates as compared to recipient was found [4] . Subsequently, many studies other configurations. However, one of the features of reported the impact of several antigens on graft surthe HLA system is its enormous polymorphism. The vival. The presence of an immunogenic HLA molecule consequence is that even in very large organizations on donor cells in the context of the HLA type of the possessing a significant pool of donors and recipients, recipient constituted the basis of the taboo concept these optimal matches can be provided only for 10 [1 ] [2] . This led workers to conceive that some combinato 22% [2] of the patients. For the others, only partially tions were detrimental, as opposed to others which matched organs can be given. One of the enigmas of were non-immunogenic and thus permissible [5] . The transplantation immunology is the existence in these obvious consequence of these observations was the patients bearing a mismatched kidney of a subset of possibility of offering partially matched organs to an subjects displaying an unexpected prolonged graft sur-additional set of patients without jeopardizing the vival. The role of the HLA system in this paradox has graft. However, prospective applications for matching never been clearly understood.
in clinical transplantation was difficult in view of the A method that has been used to clarify this issue lack of a clear definition of the molecular basis standing was to individualize specific antigens in the recipient behind this state of unresponsiveness. that conferred either a good or a bad prognosis to the An opening came from investigations made to widen graft and reflecting a state of responsiveness of the the scope of permissible mismatches by reducing the HLA polymorphism. One of the approaches [5] was to define histocompatibility in terms of public deter- and defining CREGs (cross reacting groups). The more recently the Bw6 motif have been identified as one of their targets. Later on, KIR were identified on analysis of the primary sequence of each antigen belonging to these CREGs displays the existence of T cell. Then, systematic studies using CML combinations in which responder and stimulator share specific residues specific for each of them. These sequences represent highly conserved regions of HLA class I HLA antigens started. Some inhibitory combinations have already been identified. Among them, the sharing antigens. In order to reduce DR antigens, public determinants represented by supertypic antigens DR52, of the Bw4 epitope conferred a marked inhibition [9 ] .
Thus sequences exist in the HLA molecules that are DR53, and DR51 encoded by DRB3, DRB4, and DRB5 genes respectively were used. Surprisingly, a common to many antigens and block the effector mechanisms involved in rejection. This is illustrated by retrospective study showed that matching using these simplified determinants yielded results comparable to the observation made in clinical bone marrow transplantation in which signal transduction by KIR those obtained by using conventional antigens [1] . Thus minimization of the HLA polymorphism by this appears to provide a protective effect for the HLA mismatched graft [9 ] . Similar inhibitory receptors have approach was clinically relevant and could lead to a considerable increase of the number of patients that been described for DR antigens [10 ] . Whether these receptors will help us to better understand the DR5 could benefit from a suitable transplant.
Do receptors for these simplified determinants exist? and DR6 effects remains a question to answer. Our current understanding of some mechanisms What could be the intracellular mechanisms that are triggered by them? These questions can now be involved in the DR effect is based upon observations made after planned blood transfusion in humans [11] addressed in the light of the recent description of various inhibitory processes potentially involved in and after marrow infusion in animals [12] . A number of studies have indeed found that one HLA haplotype allorecognition. Despite the fact that they do not yet provide practical answers, their understanding could or DR-matched pretransplant blood transfusions improve kidney graft prognosis in human [11 ] . modify in the future our view of matching. One of the mechanism that could operate is the release by the Likewise, administration of donor bone marrow sharing one DR antigen also increases kidney graft survival graft of inhibitory HLA molecules. Soluble HLA class I molecules of donor origin have been identified in the in monkey [12] . In this particular model, appearance of veto cells has been described. One hypothesis that serum of patients with an allograft [6 ] . They are endowed with the capacity to inhibit cell-mediated has been put forward for the DR shared pretransplant blood transfusion is the downregulation of recipient lympholysis (CML) by inducing the apoptosis of alloreactive CD8 cytotoxic T lymphocytes (CTL). This phe-CD4+ cells induced by donor's peptides presented by matched class II molecules [11 ] . In a study evaluating nomenon represents a novel process contributing to tolerance induction [6 ] . The comprehension of the the production of the immunosuppressive cytokine IL-10 during MLR, we found that DR-sharing commode of action of soluble HLA has been further facilitated by the use of synthetic peptides correspond-binations were characterized by a release of IL-10 exerting a maximal control of gamma interferon, which ing to functionally important HLA regions. Peptides specific for alleles and for conserved regions of the a3 is a pivotal cytokine of the rejection process [13 ] .
We have now entered an era of comprehensive domain of HLA class I molecules (Bw4/Bw6 epitopes) have been constructed. Both have also been shown to examination of alloreactivity. There is no doubt that the key of our understanding of the mysterious permissbe effective in blocking CML.
Another mechanism that has been individualized in ible and taboo mismatches lies in the molecular factors governing rejection. This evolving knowledge of the this peculiar setting is the binding of the peptide to two members of the heat shock protein (HSP) family alloreactive response will certainly allow us to extrapolate the previous epidemiological data to a future donor that are constitutively expressed (HSC 70 ) or heatinducible (HSP 70) [7] . It is similar to those of selection. cyclosporin and FK 506 on the immunophilins. Thus these soluble HLA molecules can induce tolerance by at least two mechanisms: apoptosis and inhibition of in alloreactivity, since this region has been involved in between specific HLA combinations and probability of kidney These receptors constitute a novel mechanism implicallograft loss: the taboo concept. Lancet 1996; 348: 850-853 ated in downregulation of allorecognition [8] . KIR 
Introduction
CsA (Neoral ) and that it decreases the rate of chronic rejection. Clinically, the most striking difference Most of the chemical immunosuppressants currently between FK 506 and CsA is that FK 506 can reverse used in human transplantation were not designed for steroid-resistant acute rejection [1 ] . Initially it was this purpose. The details of exactly how they exert licensed for this purpose. This effect was indeed unextheir immunosuppressive effects are still largely pected and the reason for the difference between unknown. This ignorance not only reduces the selective cyclosporin A and FK 506 remains unclear, considering targeting of the drug but makes it difficult to avoid the way the two drugs act, and given their similar side-effects. Nevertheless, these new drugs represent a nephrotoxicity profiles. significant advance in clinical immunosuppression and Both CsA and FK 506 bind to immunophilins (CsA they have helped to increase our knowledge of lymphoto cyclophilin A and FK 506 to FKBP 12) and both cyte activation that leads to graft rejection. But a inhibit the peptidyl prolyl cis-trans isomerase activity better understanding of these pathways is still needed of the binding molecules. Although these enzymes to improve the efficacy and safety profiles of these drugs and to design new immunosuppressants with assist in the de novo folding of nascent proteins during synergistic actions. This short review is restricted to translation and may function as chaperones in protein the drugs that are being developed for use in clinical trafficking and secretion, the inhibitory actions of CsA transplantation. Other molecules might also be very and FK 506 are not sufficient to explain the immunopromising for elucidating the molecular pathways fol-suppressive action. One of the main, but possibly not lowing allogeneic activation, but at present they are the only, target inhibited by these cyclophilinA/CsA not developed for use in transplantation, and hence and FKBP 12/FK 506 complexes is calcineurin, a will not be discussed.
serine threonine phosphatase that plays a pivotal role in the transcription of cytokines after T-cell activation [2] . Calcineurin has two subunits, the catalytic
Tacrolimus (FK 506)
calcineurin A (CNA) and the regulatory calcineurin B (CNB) that must bind the Ca2+/calmodulin complex FK 506 was shown to prolong allograft survival in in order to be functional after T-cell activation. This animals just 10 years ago. Since that time it has been binding releases an autoinhibitory domain from CNA, registered in several countries for primary immunosup-resulting in the activation of this phosphatase. pression in liver and kidney allografts. As a primary Cyclophilin/CsA and FKBP 12/FK 506 complexes immunosuppressive drug, FK 506 is more effective bind to an overlapping region of CNA that also than cyclosporin (CsA, Sandimmun) but it has yet to interacts with CNB, and this binding inhibits allosterically the catalytic site of the enzyme but not the Most studies have focused on the nuclear factor of most significant differences between them may be in their effects on the TGF b pathway. CsA increases the activated T cells (NFAT ) which has two components, a T-cell-specific cytoplasmic subunit, NF-ATc, and a synthesis of TGF b in various cells, including T lymphocytes, endothelial and renal cells [9] , whereas nuclear subunit, NF-ATn, composed of c-fos and c-jun (related to AP1). Stimulation of T cells results in FK 506 does not. TGF b acts as an immunosuppressant by interfering with the cyclin-E/cyclin increased intracellular calcium, and this activates calcineurin. The activated enzyme dephosphorylates kinase 2 complex involved in the cell cycle, and thus inhibiting cell proliferation. However, a sustained NF-ATc and this transcription factor is then translocated into the nucleus, where it associates with AP-1 elevation of TGF b may stimulate smooth-muscle proliferation, excessive matrix deposition, activate the on their respective DNA binding sites [4 ] . These sites are present on the promoter of various cytokines, and endothelin gene, and so cause pathological fibrogenesis, HTA and chronic rejection. It has also been reported the binding of NF-AT is crucial for the transcription of several cytokines including IL-2. The inactivation that FK BP12 is associated with type 1 receptors of the TGF b family and that FK 506 decreases this of calcineurin in T cells by FK 506 and CsA results not only in the inhibition of the migration of NF-ATc interaction [10] . However, the functional significance of this interaction remains to be determined. In clinical to the nucleus, but also in the inhibition of other transcription factors involved in cytokine transcription. practice, HTA seems to be less frequent in patients treated with FK 506 than in transplant patients given The activation of jun N-terminal kinase (JNK) in T cell is calcineurin dependent and both FK 506 and CsA and it has been reported that the kidney grafts in FK 506 treated patients have an extended half-life, CsA inhibit the activation of jun [5 ] .
Similarly, FK 506 and CsA prevent the translocation suggesting less chronic rejection. It is also suspected that part of the immunosuppresof NFkB into the nucleus following T-cell activation [5] . NFkB is found in the cytoplasm of unactivated sive action of FK 506 is mediated via the activation of glucocorticoid receptors (GR). Untransformed GR, T cells associated with its inhibitor I-kB. When these cells are activated I-kB is phophorylated and dissoci-which do not bind to DNA, are heteromeric structures containing the hormone binding receptor and the heat ates from NF-kB, allowing NFkB to migrate into the nucleus, where it is involved in the transcription of shock proteins (hsp), hsp 70 and hsp 56. Human hsp 56 is also an immunophilin that can bind FK 506 various cytokines. FK 506 and CsA inhibit certain I-kB kinases, so preventing the dissociation of NFkB and rapamycin. FK 506 potentiates GR-mediated transcription by increasing the hormone-binding affinity of from its inhibitor.
The targeting of various transcription factors in the GR and GR translocation [11 ] . This could explain the steroid-sparing effect of FK 506, and could parti-T cells explains that these drugs prevent the transcription of many cytokines including IL-2, IL-3, IL-4, cipate to the reversal of acute rejection produced by FK 506. However, a new GR heterocomplex has IL-5, IFNc, TNFa, GM-CSF and CD-40L. But all the cytokines are not downregulated; for example, IL10 recently been discovered that contains cyclophilin 40 (Cyp 40 ) along with hsp 90. Cyp 40 binds CsA and transcription is not affected by FK 506 or CsA. The targeting of NF-kB by FK 506 and CsA also explains like FK 506, CsA increases GR transactivation [11 ] .
In addition, both FK 506 and CsA inhibit the multidthe inhibition of the synthesis of IL-2 and IL4 receptors in activated T and B cells. However, calcineurin inhibi-rug resistance pump (MDR) competing for the drugbinding sites of P-glycoprotein, thereby increasing the tion may be incomplete in vivo; for example, it has been shown that CsA only reduces calcineurin activity intracellular concentration of drugs [11 ] . Hence the interaction of FK 506 with the steroid transduction by 50% in lymphocytes from renal transplant patients [6 ] .
pathway does not seem to account for its unique ability to reverse established acute rejection. Some of the molecular pathways common to CsA and FK 506, and possibly involving calcineurin inhibiOne explanation for the different in vivo effects of FK 506 and CsA could be the specific action of FK 506 tion, might be detrimental to the induction of tolerance. These compounds inhibit the apoptosis that follows (and rapamycin) in regulating the intracellular calciumrelease channels. FKBP 12 is physically associated activation of T cells (AICD: activation induced cell death) by decreasing the transcription of Fas-ligand, with the ryanodine receptor (RyR) and with the inositol 1,4,5-triphosphate receptor (InsP3R). inhibiting various transcription factors involved in apoptosis (e.g. NUR 77 and MEF2), and by increasing Calcineurin is physiologically associated with IP3R-FKBP 12 and RyR-FKBP 12 receptor complexes and the synthesis of bcl-2 [7 ] .
These drugs also modulate cyclic-AMP-dependent this interaction can be disrupted by FK 506 (and rapamycin), resulting in the loss of the Ca2+ oscillasignalling, decreasing the activities of cAMP dependent protein kinase A and of the cAMP-responsive element tions thought to be necessary for T-cell activation [12 ] .
Graft rejection depends on an influx of lymphocytes binding protein (CREB) [8] . These actions could modulate the immunosuppressive properties of the from the circulation into the graft in response to locally secreted chemotactic factors. There is evidence that drugs and may be involved in their diabetogenic and nephrotoxic effects.
FK 506 not only inhibits the production of lymphocyte chemotactic factors, such as IL8, but also prevents the cycle. Because the RAPA-FKBP complex does not migration of lymphocytes from healthy donors and inhibit the activation of p70S6k in a cell-free system, liver allograft recipients [13] . FK 506 may act by RAPA may act upstream of p70S6k by inhibiting other inhibiting a general mechanism of chemotaxis via its kinases or activating phosphatases. The result is that ability to inhibit the protein kinase-C-mediated signal-RAPA inhibits at least two substrates, the S6 ribosomal ling pathway involved in the actin polymerization and protein thought to enhance protein synthesis, and the cytoskeletal reorganization that is a prerequisite for cAMP-responsive element modulator (CREM ) that is cell migration. The effect of FK 506 on endothelial inducing the transcription induction of the proliferating and lymphocytes adhesion molecules is more contro-cell nuclear antigen (PCNA) gene [16 ] . PCNA is an versial, but the inhibition of lymphocyte recruitment obligate processivity factor for DNA polymerase d, by FK 506 might contribute to the ability of this drug and is required for the progression of cells into the S to reverse graft rejection. phase. Inhibition of p70S6k might also be involved in We have summarized some of the new possible the RAPA-mediated inactivation of the initiation factor actions of FK 506, but we do not know which of them eIF-4E binding protein 4E-BP1, which appears to play occur in vivo, and which of them are important for its a crucial role in the control of mRNA translation. unique clinical profile in organ transplantation. It has Progression through the cell cycle requires the been suggested that the renal toxicity of FK 506 results sequential activation of cell-cycle-dependent kinases from the inhibition of calcineurin, and the recent (cdk) and cyclin complexes. RAPA has no effect on discovery of a new isoform of FKBP (FKBP 51) in protein levels of cdk2, cdk4, cyclin D, and cyclin E mice, which is restricted to T cells and which mediates but decreases the kinase activity of cdk4-cyclin D and calcineurin inhibition, may lead to the design of more cdk2-cyclin E complexes [16 ] . Their activation in midlymphocyte specific drugs [14 ] . The limitation of such to-late G1 phase involves elimination of the cyclincompounds could be that part of the FK 506 renal dependent kinase inhibitor p27 kip1 from these cdk/ toxicity ( but not CsA toxicity) is due to the activation cyclin complexes. RAPA prevents the elimination of of NF-kB in fibroblasts and mesangial cells, resulting p27 and blocks the activation of cdk4/cyclinD and in increased IL-6 production in the kidney [15] .
cdk2/cyclin E complexes. Consequently, downstream events are inhibited: hyperphosphorylation of retino-
Sirolimus (rapamycin)
blastoma protein (Rb) and dissociation of the Rb-E2F complex. The decreased activity of the E2F transcription factors results in downregulation of the cell cycle Although rapamycin (RAPA) and FK 506 are structurproteins, cdc2, cyclin A, and of a serine threonine ally related macrolide antibiotic compounds, they cause immunosuppression by very different mechanisms. kinase required for transcriptional activity. Whereas FK 506 inhibits T-cell proliferation in the Inactivation of Rb might also block other pathways G0-G1 phase, RAPA prevents the progression of T involved in cell proliferation or differentiation such as lymphocytes and other cells from G1 to the S phase inhibition of RNA polymerases 1 and 3. and, in contrast to FK 506, blocks both calcium-RAPA also inhibits the transcription of Bcl-2, a dependent and calcium-independent signalling path-proto-oncogene that may be critical for cell cycle ways in T and B cells.
progression. The reduced expression of Bcl-2 could RAPA binds to the same immunophilin as does also favour the apoptosis of activated lymphoid cells. FK 506, FKBP 12, to form a drug-immunophilin comIt has also been reported recently that RAPA preplex. This complex cannot bind to calcineurin and vents the CD28-mediated downregulation of IkBa, RAPA does not inhibit early T-cell activation or dir-resulting in inhibition of the nuclear translocation of ectly reduce the synthesis of cytokines. The target c-rel. c-Rel is a CD28 response element binding factor proteins of this complex were first identified in yeasts, that causes sustained upregulation of IL-2 gene expresand have been called TOR 1 and TOR 2. A mammalian sion [16 ] . RAPA effector protein (mTOR, FRAP, RAFT, SEP)
These various ways in which RAPA can interfere has recently been identified [16 ] . A mutation in this with the progression of cells from G1 to S phase protein confers resistance to RAPA. mTOR possesses explain why it is not an effective inhibitor of cytokine a phosphatidyl inositol-3 kinase domain but this activsynthesis in vitro, but antagonizes the effects of cytoity is not inhibited by RAPA. On the other hand, kines and growth factors in activated T and B cells. activated mTOR undergoes autophosphorylation, and
The activity of RAPA is not limited to cells of the this is blocked by RAPA. Although neither the funcimmune system and its other important action is to tional properties nor the proximal target of mTOR inhibit the proliferation of smooth-muscle cells stimuhave yet been determined, RAPA is known to affect lated with b-FGF and PDGF. several critical biochemical events in the middle to late RAPA is now undergoing phase III clinical trials in G1 phase of the cell cycle, but there is still much to kidney transplantation Two major types of clinical do to tie up the many loose ends of this puzzle [16 ] . trials are in progress. Some protocols take advantage RAPA inhibits the activation of 70-kDa S6 kinase of the synergy between CsA and RAPA, whereas others ( p70S6k), an enzyme implicated in the regulation of various cellular processes that are critical in the cell combine RAPA with other non-nephrotoxic drugs. molecular chaperoning, peptide loading of MHC mole-
Mycophenolate mofetil
cules, and translocation of proteins from the cytoplasm to the nucleus. DSG seems to prevent hsp 70 interacting Mycophenolate mofetil is an ester prodrug of the active with NFkB, so impeding the nuclear translocation of immunosuppressant mycophenolic acid (MPA). This this factor and inhibiting the transcription of NF-kBdrug acts at a late stage of lymphocyte proliferation, dependent genes such as IL-1, IL-6, IL-8, TNF, MCP, beyond the steps which are inhibited by either FK 506 iNOS, IL-2R, and the k light chain [21] . or rapamycin. It is a non-competitive, reversible inhibBrequinar and leflunomide are two other potential itor of inosine monophosphate dehydrogenase interesting immunosuppressive drugs, but their devel-( IMPDH) [17 ] . IMPDH is critical for the de novo opment for use in clinical transplantation has now synthesis of purines during lymphocyte activation.
been stopped. MPA binds to the nicotinamide site on IMPD and Although most of the immunosuppressants currently mimics the inhibition of IMPDH by nicotinamide in clinical development were discovered by screening adenine dinucleotide (NAD) [18] . Most cells proliferprogrammes seeking new antibiotics or antitumour ate normally with only an intact salvage pathway, drugs, they have contributed a great deal to the unravwhereas T and B cells require an intact purine biosynelling of the complex biochemical pathways that medithetic pathway. In addition, the type II isoform which ate the immune response to an allograft. The growing might be predominant in activated lymphocytes is body of new knowledge should make it possible to more sensitive to inhibition by MPA than the type I.
design new classes of drugs with greater specificity and The effects of MPA are directly attributable to the fewer toxic effects. depletion of guanosines nucleotides [17] . This results in decreases in the activities of PRPP synthetase and ribonucleotide reductase, so inhibiting DNA and RNA References synthesis, a decreased transfer of mannose to mem-Introduction dependent [2 ] and progressive [6 ] and the magnitude of this fall in GFR in the first year (or perhaps the The capacity of cyclosporin to induce both reversible first few months) appears to be the key indicator of and irreversible renal dysfunction associated with morpoor renal outcome. Although in some cases withphological injury has limited its clinical use. The mechdrawal or dose reduction of cyclosporin may stabilize anisms responsible for this nephrotoxicity remain renal function [5, 7] , this is by no means the rule [6 ] obscure, although the initial changes are haemoand even if function remains stable, proteinuria and dynamic and a consequence of the drug's ability morphological injury can increase [2 ] . Similarly, irreto vasoconstrict preglomerular resistance vessels.
versible loss of renal function is reported after liver, Whereas the native kidney is particularly sensitive to pancreas and bone marrow transplantation and in cyclosporin, the renal allograft appears protected from patients with uveitis, insulin-dependent diabetes, progressive injury. This observation may pave the way rheumatoid arthritis, and psoriasis [8] , even with doses for future pharmacological or interventional therapies as low as 5 mg/kg/day. The method of cyclosporin directed towards the preservation of renal function.
administration may be relevant since GFR was reported to improve if cyclosporin was given once rather than twice daily to stable heart-transplant recipi-
Cardiac transplantation
ents [9 ] . It is probable that the relationship between progressive dysfunction and either dose or levels of Chronic cyclosporin nephrotoxicity is responsible for cyclosporin is partly idiosyncratic. a high (10%) prevalence of end-stage renal failure ( ESRF ) which occurs by 10 years after cardiac transStructure plantation [1] [2] [3] . Still worse results are found following heart and lung transplantation with a 10% prevalence Renal histology from native kidneys shows a variable of ESRF within only 5 years [3] . amount of both global and segmental glomerular sclerosis [2, 10] with surviving glomeruli tending to be Function larger, an appearance consistent with glomerular hyperfiltration and increasing proteinuria. In contrast The renal vasoconstriction leads to renal hypoper-to native kidneys, glomeruli in renal allografts are fusion and salt and water retention associated with spared. These changes appear to be secondary to the hypertension. Consistent with these events, there are progressive arteriolar vasculopathy leading to the increased numbers of renin granules present in the glomerular ischaemia and tubular atrophy. This patjuxtaglomerular apparatus and in hilar arterioles, and tern of loss initially results in a characteristic appearincreased expression of AT1 receptors [4] .
ance of striped tubular atrophy and fibrosis which After cardiac transplantation there is early loss of begins in the medulla and progresses to the medullary rays of the cortex. In a recent study of renal pathology 
